V

VA Long Beach Healthcare System | Tibor Rubin VA Medical Center

Research site

(Unclaimed)

Location

5901 East 7th Street, Long Beach, California, United States of America

Site insights

Top conditions

Top treatments

Peginterferon

Ribavirin

Daclatasvir

Carboplatin

Telaprevir

Cisplatin

Sofosbuvir

Filgotinib

Talazoparib

Venetoclax

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 92 total trials

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting

Giant Cell Arteritis (GCA)

Drug: Upadacitinib

Other: Placebo

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access

Active, not recruiting

Vascular Access

Hemodialysis

Other: Hemodialysis

Procedure: Arteriovenous fistula (AVF)

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting

Ulcerative Colitis

Drug: Filgotinib

Drug: Placebo

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting

Prostate Cancer

Drug: Placebo plus enzalutamide

Drug: talazoparib plus enzalutamide

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting

mCRPC

Drug: Talazoparib with enzalutamide

Drug: Placebo with enzalutamide